Asarfi Hospital Board of Directors

Get the latest insights into the leadership at Asarfi Hospital. Learn about the experienced professionals guiding the company's strategy and governance.

NamePosition
Mr. Udai Pratap Singh Managing Director
Mrs. Madhuri Singh Executive Director
Mr. Gopal Singh Executive Director
Dr. Sukanti Kumar Das Non Executive Director
Mrs. Rajkumari Sharma Independent Director
Mr. Amit Kumar Barnwal Independent Director

Asarfi Hospital Share price

ASARFI

121

1.20 (1.00%)
Last updated on 4 Sep, 2025 | 13:48 IST
BUYSELL
Today's High

124.55

Today's Low

118.25

52 Week Low

52.84

52 Week High

150.00

The current prices are delayed, login to your account for live prices

Asarfi Hospital FAQs

The board at Asarfi Hospital consists of experienced professionals, including Mr. Udai Pratap Singh , Mrs. Madhuri Singh , and others, overseeing the company’s strategic and corporate governance.

Directors at Asarfi Hospital are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.

As of the latest update, Mr. Udai Pratap Singh is the current chairman at Asarfi Hospital.

Executive directors at Asarfi Hospital are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.

Yes, Asarfi Hospital adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.

At Asarfi Hospital, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.